← Back to calculator
Published Phase 2 human RCT
A plain-language overview of survodutide — what it is, its once-weekly subcutaneous route, and its investigational (non-approved) regulatory status — with the reconstitution and mg-to-units arithmetic handled separately on the survodutide dosage calculator.
Peptide Calculator X
Reconstitution / draw volume / syringe units / supply-chain
Arithmetic checks out. Confirm clinically, against the label, and against the actual vial before any use.
Independent check - dose mg / concentration mg/mL = volume. U-100 units = mL x 100.
Reverse: pick a dose and the units you want it to read, then calculate diluent to add.
Survodutide: reference record
| Regulatory status | Investigational; no FDA/UK/EU marketing approval |
|---|---|
| Route | Subcutaneous |
| Dosing frequency | Once weekly |
| Published range | 0.6–4.8 mg |
| Evidence basis | Published Phase 2 human RCT |
| Common vial sizes | 10 |
Sources
- PubMed - PMID 38330987Basis for the regulatory status, route, frequency and published range in the table above. Source last checked 2026-06-24
What is Survodutide?
Survodutide is an investigational injectable peptide acting at both the GLP-1 and glucagon receptors, studied for weight management in early-phase clinical trials.
Is Survodutide FDA-approved?
No. Survodutide is investigational with no FDA, UK or EU marketing approval. The published figures come from a clinical trial rather than an approved label.
How is Survodutide given?
Subcutaneously, once weekly, in the published Phase 2 dose-finding trial, with escalation carried out over an extended period under protocol control.
What are the known safety concerns with Survodutide?
The trial escalation was supervised, and the published range is not a personal titration schedule. Long-term safety has not been established through an approval process.
Phase 2 dose-finding tested 0.6, 2.4, 3.6 and 4.8 mg weekly with 20-week escalation
Study range only; no approved commercial concentration or label.
Trial escalation was controlled; the published range is not a personal titration schedule.
Supply-chain quality · Finnrick
Avg quality score
6.8
/10
Purity range
98.39
–
99.95
%
Qty divergence
±
20
%
Vendors · samples
7
·
27
Common vial sizes
10
mg
Test window
Apr 2025 - May 2026
Related calculators & comparisons
COMPARISONS
Browse all peptides →